Avidity Partners 13F holdings, Q4 2022
Holdings as of December 31, 2022 · filings on SEC EDGAR · latest filing →
Avidity Partners disclosed 84 US equity positions worth $4.3bn in its Q4 2022 13F filing. The largest position was ARGX at 5.5% of the reported book, followed by UTHR and NBIX. Against the Q3 2022 filing, it opened 13 new positions, added to 25 and reduced 11 among the top 50 holdings.
What did Avidity Partners own in Q4 2022? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2022 |
|---|---|---|---|---|---|---|---|
| 1 | ARGX ARGENX SE | Healthcare | 5.5% | $236.8m | 625,000 | 27% | added |
| 2 | UTHR UNITED THERAPEUTICS CORP DEL | Healthcare | 5.1% | $218.4m | 785,500 | -19% | reduced |
| 3 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 5.0% | $212.6m | 1,780,000 | -4% | reduced |
| 4 | AKERO THERAPEUTICS INC | 4.9% | $209.6m | 3,825,000 | 23% | added | |
| 5 | PROTHENA CORP PLC | 4.2% | $177.9m | 2,953,000 | 50% | added | |
| 6 | ARVN ARVINAS INC | Healthcare | 4.0% | $169.3m | 4,950,000 | 14% | added |
| 7 | BSX BOSTON SCIENTIFIC CORP | Healthcare | 3.5% | $150.7m | 3,256,700 | 28% | added |
| 8 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 3.5% | $149.2m | 5,861,000 | 5% | added |
| 9 | RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 3.2% | $138.5m | 2,990,000 | 46% | added |
| 10 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 3.2% | $136.7m | 1,055,000 | 11% | added |
| 11 | MDGL MADRIGAL PHARMACEUTICALS INC | Healthcare | 2.9% | $124.8m | 430,000 | – | new |
| 12 | UHS UNIVERSAL HLTH SVCS INC | Healthcare | 2.7% | $116.3m | 825,600 | – | new |
| 13 | JAZZ JAZZ PHARMACEUTICALS PLC | Healthcare | 2.7% | $115.9m | 727,541 | 129% | added |
| 14 | ZNTL ZENTALIS PHARMACEUTICALS INC | Healthcare | 2.4% | $103.7m | 5,150,000 | 22% | added |
| 15 | ACHC ACADIA HEALTHCARE COMPANY IN | Healthcare | 2.2% | $95.9m | 1,165,000 | -16% | reduced |
| 16 | SGRY SURGERY PARTNERS INC | Healthcare | 2.0% | $86.7m | 3,112,000 | 1063% | added |
| 17 | DXCM DEXCOM INC | Healthcare | 2.0% | $85.7m | 756,800 | 62% | added |
| 18 | AZN ASTRAZENECA PLC | Healthcare | 1.9% | $81.4m | 1,200,000 | 113% | added |
| 19 | LLY LILLY ELI & CO | Healthcare | 1.9% | $79.4m | 217,000 | -78% | reduced |
| 20 | PCVX VAXCYTE INC | Healthcare | 1.8% | $77.5m | 1,615,400 | 157% | added |
| 21 | AVIDITY BIOSCIENCES INC | 1.7% | $72.7m | 3,275,000 | 26% | added | |
| 22 | NTRA NATERA INC | Healthcare | 1.7% | $72.3m | 1,798,900 | 4% | added |
| 23 | IDYA IDEAYA BIOSCIENCES INC | Healthcare | 1.6% | $69.5m | 3,824,800 | 3% | added |
| 24 | IMCR IMMUNOCORE HLDGS PLC | Healthcare | 1.5% | $65.9m | 1,154,000 | -44% | reduced |
| 25 | ALT ALTIMMUNE INC | Healthcare | 1.5% | $65.6m | 3,990,000 | 49% | added |
| 26 | RVMD REVOLUTION MEDICINES INC | Healthcare | 1.4% | $59.0m | 2,475,000 | 7% | added |
| 27 | KARUNA THERAPEUTICS INC | 1.4% | $58.8m | 299,000 | -31% | reduced | |
| 28 | ARWR ARROWHEAD PHARMACEUTICALS IN | Healthcare | 1.3% | $55.8m | 1,375,000 | 10% | added |
| 29 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 1.2% | $51.7m | 670,000 | -56% | reduced |
| 30 | VRTX VERTEX PHARMACEUTICALS INC | Healthcare | 1.2% | $49.7m | 172,000 | -66% | reduced |
| 31 | LEGN LEGEND BIOTECH CORP | Healthcare | 1.1% | $48.4m | 970,000 | – | new |
| 32 | KEZAR LIFE SCIENCES INC | 1.1% | $47.7m | 6,782,400 | 25% | added | |
| 33 | PLRX PLIANT THERAPEUTICS INC | Healthcare | 1.0% | $43.3m | 2,240,400 | 13% | added |
| 34 | VENTYX BIOSCIENCES INC | 1.0% | $42.1m | 1,285,000 | – | new | |
| 35 | ICLR ICON PLC | Healthcare | 1.0% | $41.8m | 215,000 | – | new |
| 36 | DGX QUEST DIAGNOSTICS INC | Healthcare | 0.9% | $40.4m | 258,000 | – | new |
| 37 | BIO BIO RAD LABS INC | Healthcare | 0.9% | $38.8m | 92,200 | -36% | reduced |
| 38 | BELLUS HEALTH INC NEW | 0.9% | $37.8m | 4,599,998 | 6% | added | |
| 39 | THC TENET HEALTHCARE CORP | Healthcare | 0.8% | $35.0m | 717,300 | – | new |
| 40 | KPTI KARYOPHARM THERAPEUTICS INC | Healthcare | 0.8% | $32.8m | 9,633,911 | – | new |
| 41 | BNTX BIONTECH SE | Healthcare | 0.8% | $32.4m | 215,400 | – | new |
| 42 | VERVE THERAPEUTICS INC | 0.7% | $30.3m | 1,565,000 | 50% | added | |
| 43 | RCKT ROCKET PHARMACEUTICALS INC | Healthcare | 0.7% | $29.9m | 1,527,087 | – | new |
| 44 | INTRA-CELLULAR THERAPIES INC | 0.6% | $26.7m | 504,000 | -64% | reduced | |
| 45 | ARQT ARCUTIS BIOTHERAPEUTICS INC | Healthcare | 0.6% | $26.0m | 1,755,000 | 121% | added |
| 46 | PROMETHEUS BIOSCIENCES INC | 0.5% | $22.4m | 204,000 | – | new | |
| 47 | NTLA INTELLIA THERAPEUTICS INC | Healthcare | 0.5% | $22.3m | 638,200 | -36% | reduced |
| 48 | VIR VIR BIOTECHNOLOGY INC | Healthcare | 0.5% | $21.5m | 850,000 | – | new |
| 49 | PHAT PHATHOM PHARMACEUTICALS INC | 0.5% | $21.3m | 1,900,000 | -0% | held | |
| 50 | BHVN BIOHAVEN LTD | Healthcare | 0.5% | $20.7m | 1,492,000 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.